{"protocolSection":{"identificationModule":{"nctId":"NCT00085839","orgStudyIdInfo":{"id":"OSI-774-201"},"organization":{"fullName":"Astellas Pharma Inc","class":"INDUSTRY"},"briefTitle":"Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2","officialTitle":"A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status"},"statusModule":{"statusVerifiedDate":"2012-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-02"},"primaryCompletionDateStruct":{"date":"2007-03","type":"ACTUAL"},"completionDateStruct":{"date":"2007-03","type":"ACTUAL"},"studyFirstSubmitDate":"2004-06-15","studyFirstSubmitQcDate":"2004-06-16","studyFirstPostDateStruct":{"date":"2004-06-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-03-28","resultsFirstSubmitQcDate":"2011-03-28","resultsFirstPostDateStruct":{"date":"2011-04-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-08-06","lastUpdatePostDateStruct":{"date":"2012-08-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"OSI Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Tarceva","NSCLC","EGFR","ECOG Performance Status 2","erlotinib","Non-Small Cell Lung Cancer","OSI-774"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":103,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Erlotinib","type":"EXPERIMENTAL","description":"Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy","interventionNames":["Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)"]},{"label":"Standard Chemotherapy","type":"ACTIVE_COMPARATOR","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles","interventionNames":["Drug: Combination carboplatin and paclitaxel"]}],"interventions":[{"type":"DRUG","name":"Tarceva (Trademark) (erlotinib HCl, OSI-774)","description":"Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy","armGroupLabels":["Erlotinib"]},{"type":"DRUG","name":"Combination carboplatin and paclitaxel","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles","armGroupLabels":["Standard Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival","description":"Median time until disease progression. Disease progression defined as radiological and/or symptomatic disease progression or death in absence of progression.","timeFrame":"Until time of disease progression (maximum 5 months)"}],"secondaryOutcomes":[{"measure":"Overall Survival","description":"Median number of months from first study treatment until time of death","timeFrame":"From first study treatment until time of death (maximum 26.8 months)"},{"measure":"Best Tumor Response","description":"Change in size of tumor: Complete Response (CR) = no measurable tumor; Partial Response (PR) = 30% decrease in size of measurable tumor; Stable Disease (SD) = measurable tumor size has not changed; Progressive Disease (PD) = measurable tumor 20% larger than at baseline.","timeFrame":"While receiving study treatment (maximum 60 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage IIIB or IV Nonsmall cell lung cancer (NSCLC)\n* No prior chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 2\n* Clinically or radiologically measurable disease per RECIST criteria\n\nExclusion Criteria:\n\n* Gastro-intestinal abnormalities\n* Any concurrent anticancer therapy\n* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors of any kind\n* Other active malignancies\n* Uncontrolled brain metastases\n* Severe abnormalities of the cornea\n* Significant cardiac disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"California Cancer Care, Inc.","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"Sharp Clinical Oncology Research","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Holy Cross Hospital","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"University of Miami","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Mount Sinai Cancer Center","city":"Miami Beach","state":"Florida","zip":"33140","country":"United States","geoPoint":{"lat":25.79065,"lon":-80.13005}},{"facility":"Evanston Northwestern Healthcare","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Oncology/Hematology Associates of Central Illinois","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Norton Healthcare, Inc.","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Maryland Hematology/Oncology Associates","city":"Baltimore","state":"Maryland","zip":"21237","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"VA Sierra Nevada Health Care System","city":"Reno","state":"Nevada","zip":"89502","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Weill Medical College of Cornell University","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"FEK Addo, PC","city":"Bismarck","state":"North Dakota","zip":"58503","country":"United States","geoPoint":{"lat":46.80833,"lon":-100.78374}},{"facility":"Gabrail Cancer Center","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"University Hospitals of Cleveland","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43210-1240","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Thomas Jefferson University Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Charleston Hematology Oncology","city":"Charleston","state":"South Carolina","zip":"29403","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"East Tennessee Oncology/Hematology, PC","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Sarah Cannon Cancer Center","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}}]},"referencesModule":{"references":[{"pmid":"18281658","type":"RESULT","citation":"Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008 Feb 20;26(6):863-9. doi: 10.1200/JCO.2007.13.2720."}],"seeAlsoLinks":[{"label":"OSI Pharmaceuticals website","url":"http://www.osip.com"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The first patient was treated 17 March 2004 and the last patient completed 19 March 2007.","groups":[{"id":"FG000","title":"Erlotinib","description":"Erlotinib 150 mg/day continuous therapy"},{"id":"FG001","title":"Standard Chemotherapy","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"51"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"51"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Erlotinib","description":"Erlotinib 150 mg/day continuous therapy"},{"id":"BG001","title":"Standard Chemotherapy","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"103"}]}],"measures":[{"title":"Age Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69","lowerLimit":"47","upperLimit":"82"},{"groupId":"BG001","value":"67","lowerLimit":"47","upperLimit":"84"},{"groupId":"BG002","value":"68","lowerLimit":"47","upperLimit":"84"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"52"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"51"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"68"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"22"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"Median time until disease progression. Disease progression defined as radiological and/or symptomatic disease progression or death in absence of progression.","populationDescription":"All patients who received at least 1 dose of study drug and who had both a baseline and at least one on-treatment tumor assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Until time of disease progression (maximum 5 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib 150 mg/day continuous therapy"},{"id":"OG001","title":"Standard Chemotherapy","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"51"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","lowerLimit":"1.28","upperLimit":"2.69"},{"groupId":"OG001","value":"3.52","lowerLimit":"1.48","upperLimit":"4.73"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Median number of months from first study treatment until time of death","populationDescription":"All patients who received at least 1 dose of study drug and who had both a baseline and at least one on-treatment tumor assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first study treatment until time of death (maximum 26.8 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib 150 mg/day continuous therapy"},{"id":"OG001","title":"Standard Chemotherapy","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"51"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.57","lowerLimit":"3.78","upperLimit":"8.25"},{"groupId":"OG001","value":"9.53","lowerLimit":"7.46","upperLimit":"15.54"}]}]}]},{"type":"SECONDARY","title":"Best Tumor Response","description":"Change in size of tumor: Complete Response (CR) = no measurable tumor; Partial Response (PR) = 30% decrease in size of measurable tumor; Stable Disease (SD) = measurable tumor size has not changed; Progressive Disease (PD) = measurable tumor 20% larger than at baseline.","populationDescription":"All patients who received at least 1 dose of study drug and who had both a baseline and at least one on-treatment tumor assessment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"While receiving study treatment (maximum 60 weeks)","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib 150 mg/day continuous therapy"},{"id":"OG001","title":"Standard Chemotherapy","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Complete Response (CR)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Partial Response (PR)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]},{"title":"Stable Disease (SD)","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"}]}]},{"title":"Progressive Disease (PD)","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"}]}]},{"title":"Unable to Determine/Not Evaluable","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3","timeFrame":"While on study drug and 30 days after last dose","description":"Adverse events are provided regardless of causality; safety population includes patients who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Erlotinib","description":"Erlotinib 150 mg/day continuous therapy","seriousNumAffected":24,"seriousNumAtRisk":52,"otherNumAffected":51,"otherNumAtRisk":52},{"id":"EG001","title":"Standard Chemotherapy","description":"Paclitaxel 200 mg/m\\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles","seriousNumAffected":13,"seriousNumAtRisk":51,"otherNumAffected":50,"otherNumAtRisk":51}],"seriousEvents":[{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Pneumonia haemophilus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Viral diarrhoea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Streptococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Cardiac fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Gastric ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Metastatic pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Pericardial effusion malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Ischaemic limb pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Hypotention","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Optic neuritis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":52},{"groupId":"EG001","numAffected":27,"numAtRisk":51}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":52},{"groupId":"EG001","numAffected":15,"numAtRisk":51}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":52},{"groupId":"EG001","numAffected":15,"numAtRisk":51}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":52},{"groupId":"EG001","numAffected":14,"numAtRisk":51}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":5,"numAtRisk":51}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Dysgeusia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":52},{"groupId":"EG001","numAffected":26,"numAtRisk":51}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Dermatitis exfoliative","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":51}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":52},{"groupId":"EG001","numAffected":23,"numAtRisk":51}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":8,"numAtRisk":51}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":52},{"groupId":"EG001","numAffected":5,"numAtRisk":51}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":6,"numAtRisk":51}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":8,"numAtRisk":51}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":7,"numAtRisk":51}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":52},{"groupId":"EG001","numAffected":16,"numAtRisk":51}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":52},{"groupId":"EG001","numAffected":12,"numAtRisk":51}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":13,"numAtRisk":51}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":10,"numAtRisk":51}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":5,"numAtRisk":51}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Chest wall pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":52},{"groupId":"EG001","numAffected":6,"numAtRisk":51}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":7,"numAtRisk":51}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":52},{"groupId":"EG001","numAffected":10,"numAtRisk":51}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":4,"numAtRisk":51}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]},{"term":"Keratoconjunctivitis sicca","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":51}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":1,"numAtRisk":51}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (6.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":51}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Medical Monitor","organization":"Astellas Pharma Global Development","email":"clinicaltrials@us.astellas.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D010330","term":"Patents as Topic"},{"id":"D017239","term":"Paclitaxel"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D018973","term":"Intellectual Property"},{"id":"D007603","term":"Jurisprudence"},{"id":"D012926","term":"Social Control, Formal"},{"id":"D004472","term":"Health Care Economics and Organizations"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}